Cisterna Biologics, Inc.

Oceanside, CA

UEI
VGCCUDX8F5P5
CAGE
9V2T6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Subcontinent Asian (Asian-Indian) American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
3349 Las Vegas Dr, Oceanside, CA 92054, USA
Website
cisternabx.com
Founded
2022
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Cisterna Biologics, Inc.

Cisterna Biologics, Inc. is a biotechnology company based in Oceanside, California, registered as a minority-owned, self-certified small disadvantaged business. The company specializes in developing innovative mRNA production technologies, focusing on creating high-quality, purified mRNA with reduced contaminants for potential therapeutic applications. As a for-profit organization, Cisterna Biologics has positioned itself at the forefront of advanced mRNA synthesis techniques, targeting improvements in mRNA purity, production efficiency, and overall therapeutic potential.

The company has secured three significant federal grant awards from prominent scientific agencies, demonstrating its commitment to advancing mRNA technology. The National Center for Advancing Translational Sciences (NCATS) awarded a $349,746 grant to develop a platform for synthesizing high-quality, purified mRNA with minimal contaminants. The National Institute of General Medical Sciences (NIGMS) provided a $350,000 grant to develop cold-adapted RNA polymerases and a proprietary purification technology in collaboration with the University of Texas-Austin. Additionally, the National Science Foundation (NSF) awarded a $274,980 SBIR Phase I grant to create a cost-efficient mRNA production platform using yeast cells, with the goal of reducing manufacturing costs by up to 90% compared to current in vitro transcription methods. These grants collectively focus on innovative approaches to mRNA production, emphasizing improved purity, reduced immune response, enhanced therapeutic efficacy, and significantly lower production costs.

Quick answers

What is Cisterna Biologics, Inc.'s UEI?

Cisterna Biologics, Inc.'s Unique Entity ID (UEI) in SAM.gov is VGCCUDX8F5P5.

What is Cisterna Biologics, Inc.'s CAGE code?

Cisterna Biologics, Inc.'s CAGE code is 9V2T6.

What is Cisterna Biologics, Inc.'s primary NAICS code?

Cisterna Biologics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Cisterna Biologics, Inc. located?

Cisterna Biologics, Inc.'s physical address in SAM.gov is 3349 Las Vegas Dr, Oceanside, CA 92054, USA.

Is Cisterna Biologics, Inc. registered in SAM.gov?

Yes. Cisterna Biologics, Inc.'s SAM.gov registration is active through February 16, 2027.

What is Cisterna Biologics, Inc.'s most recent federal award?

Cisterna Biologics, Inc.'s most recent federal grant award is A novel approach to eliminate length impurities for high-quality mrna production - project summary with the success of… (R43TR005424), from National Center for Advancing Translational Sciences, on August 1, 2025.

On GovTribe

See Cisterna Biologics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors